• Product NameRadotinib
• Brief DescriptionInhibitors
• Purification99.97%
• Biological ActivityRadotinib, and sometimes referred to by its investigational name IY5511, is a drug for the treatment of different types of Y, most notably Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) with resistance or intolerance of other tyrosine kinase Bcr-Abl inhibitors
• Target NameBcr-Abl inhibitor
• CAS No. 926037-48-1
• Calculated MW 530.5
• Formulation C27H21F3N8O
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cancer
  SMILES:CC1=CN(C=N1)C1=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=NC=CN=C3)=C(C)C=C2)=CC(=C1)C(F)(F)F
  Pathways:Angiogenesis; Cytoskeletal Signaling
  Receptor:Bcr-Abl1
  Boling pt:
  Melting pt:
  Solubility:DMSO: 10 mM
  Appearance:Khaki Powder
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Heo SK, et al. PLoS One. 2015 Jun 12;10(6):e0129853.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting